Paul Murphy, MD
Psychiatry · Wichita, KSNPI 1720082241
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,013 of the $18,973 with a category attached, or 79.1%. It is spread thinly across 36 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $6,175 and has fallen 70.9% since, to $1,799 in 2025. Among psychiatry clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 696 payments — averaging $27.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Lundbeck LLC$983
- plus $7K from 30 others
Across 190 payments — averaging $20,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$1.4M
- Eli Lilly$920K
- Novartis$509K
- Genentech, Inc.$459K
- Janssen Research & Development, LLC$394K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$137K
What the payments were for
- Speaking & faculty fees$3,52019%
- Food & beverage$15,01379%
- Education$4402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$3,520
- LYBALVI$2,193
- ARISTADA$1,424
- REXULTI$564
- INGREZZA$360
- ARISTADA INITIO$356
- SPRAVATO$315
- NUPLAZID$249
- LATUDA$243
- CAPLYTA$222
- Jornay PM 20mg capsules (Bottle of 100)$172
- Yupelri$125
- JORNAY PM$125
- SUBLOCADE$124
- Fanapt$123
- Austedo XR$118
- QUVIVIQ$110
- INVEGA SUSTENNA$108
- IGALMI$102
How this compares
$18,973 in reported general payments places this provider in the 90th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 48 | $56,936 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 38 | $12,128 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 64 | $5,474 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 123 | $3,558 |
| CymbaltaDuloxetine Hcl | 12 | $3,282 |
| Aripiprazole | 42 | $1,670 |
| Zolpidem Tartrate ErZolpidem Tartrate | 17 | $1,591 |
| Lorazepam | 167 | $1,346 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 30 | $1,316 |
| Bupropion XlBupropion Hcl | 85 | $1,286 |
| Clonazepam | 160 | $1,132 |
| Tranylcypromine Sulfate | 13 | $1,127 |
| Duloxetine Hcl | 41 | $863 |
| Quetiapine Fumarate | 70 | $861 |
| Alprazolam | 96 | $813 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $810 | $56,93648 claims |
| Almatica Pharma LLCSertraline Hcl | $229 | $36143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 259 psychiatry providers in Kansas.
Other psychiatry in Wichita
- Sheldon PreskornWichita$498K
- Heidi OgdenWichita$55K
- Ralph BharatiWichita$26K
- Dwight St ClairWichita$18K
- Mukhtar ShahWichita$12K
- Rex LearWichita$11K
- Lin XuWichita$9K
- Mercedes PeralesWichita$8K
- Jasmine KaurWichita$6K
- Peter SeilerWichita$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.